Over the 90-day window ending February 15, 2026, BiomX's three dominant insider ownership positions are held by Director James E Flynn (65.63K shares), Chief Executive Officer Jonathan Eitan Solomon (6.67K shares), Chief Development Officer Merav Bassan (4.19K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Israel Biofund Gp Limited Partnership Orbimed | 3,815 | 20 May, 2024 | |
| Fibrosis Foundation Cystic | 2,584 | 17 May, 2024 | |
| Chidozie Ugwumba | 830 | 14 Nov, 2022 | |
| James E Flynn | 65,632 | 03 Mar, 2025 | |
| Jonas Grossman | 103 | 17 Aug, 2021 | |
| Gbolahan Amusa | 73 | 28 Jul, 2021 | |
| Jonathan Eitan Solomon | Chief Executive Officer | 6,671 | 21 Apr, 2025 |
| Merav Bassan | Chief Development Officer | 4,189 | 21 Apr, 2025 |
| Marina Wolfson | Chief Financial Officer | 3,608 | 21 Apr, 2025 |
| Assaf Oron | Chief Business Officer | 1,358 | 18 Sep, 2024 |
| Paul J Sekhri | 3 | 30 Jul, 2021 | |
| Lynne Marie Sullivan | 3 | 30 Jul, 2021 | |
| Alan Charles Moses | 1 | 30 Jul, 2021 | |
| Russell Greig | 1 | 30 Jul, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 14 Apr, 2025 | Jonathan Eitan Solomon | Common Stock | A | 126,748 | $0.00 | 6,671 | D | A |
| 14 Apr, 2025 | Jonathan Eitan Solomon | Common Stock | A | 126,748 | $0.00 | 6,671 | D | A |
| 14 Apr, 2025 | Merav Bassan | Common Stock | A | 79,597 | $0.00 | 4,189 | D | A |
| 14 Apr, 2025 | Merav Bassan | Common Stock | A | 79,597 | $0.00 | 4,189 | D | A |
| 14 Apr, 2025 | Marina Wolfson | Common Stock | A | 68,545 | $0.00 | 3,608 | D | A |
| 14 Apr, 2025 | Marina Wolfson | Common Stock | A | 68,545 | $0.00 | 3,608 | D | A |
| 27 Feb, 2025 | James E Flynn | - | - | 65,632 | I | |||
| 27 Feb, 2025 | James E Flynn | Common Stock | A | 353,249 | $0.93 | 65,632 | I | M |
| 27 Feb, 2025 | James E Flynn | Common Stock | A | 353,249 | $0.93 | 65,632 | I | M |
| 27 Feb, 2025 | James E Flynn | - | - | 65,632 | I | |||
| 16 Sep, 2024 | Assaf Oron | Common Stock | A | 25,804 | $0.00 | 1,358 | D | A |
| 16 Sep, 2024 | Jonathan Eitan Solomon | Common Stock | A | 50,556 | $0.00 | 2,792 | D | A |
| 16 Sep, 2024 | Merav Bassan | Common Stock | A | 31,749 | $0.00 | 1,671 | D | A |
| 16 Sep, 2024 | Merav Bassan | - | - | 1,671 | D | |||
| 15 Jul, 2024 | James E Flynn | Common Stock | A | 5,883,000 | - | 2,476 | I | M |
| 15 Jul, 2024 | James E Flynn | Common Stock | A | 5,883,000 | - | 2,476 | I | M |
| 15 May, 2024 | Israel Biofund Gp Limited Partnership Orbimed | - | - | 3,815 | I | |||
| 15 May, 2024 | Israel Biofund Gp Limited Partnership Orbimed | Common Stock | D | 24,344 | $0.38 | 3,815 | I | S |
| 15 May, 2024 | Israel Biofund Gp Limited Partnership Orbimed | Common Stock | A | 9,280,408 | $0.24 | 3,822 | I | X |
| 15 May, 2024 | Fibrosis Foundation Cystic | Common Stock, par value $0.0001 per share | A | 4,778,265 | $0.00 | 2,584 | D | X |